Replay available

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Q3 2025 earnings conference call, held 2025-02-13. Replay captured from the company's public earnings webcast.

Thu, February 13, 2025 at 5:00 PMendedReplay
Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call

Hosted by

Featured presenters

Mark McPartland

Speaker Host, Investor Relations

Shawn Singh

President & Chief Executive Officer

Cindy Anderson

Chief Financial Officer

Josh Prince

Chief Operating Officer

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Vistagen Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.037 Good day. Thank you for standing by. Welcome to this agenda predicts third quarter 00:00:05.037 -- 00:00:08.781 fiscal year 2025 corporate update conference call. 00:00:08.781 -- 00:00:12.045 At this time, all participants on the list are normally mode. 00:00:12.045 -- 00:00:14.908 After the speaker's presentation, there will be a question and answer session. 00:00:14.908 -- 00:00:19.914 To ask a question during the session, you will need to press star one one on your telephone. 00:00:19.914 -- 00:00:23.538 You will then hear an automatic message advising your hand is raised. 00:00:23.538 -- 00:00:25.580 Please note that today's conference is being recorded. 00:00:25.580 -- 00:00:32.259 I will now hand the conference over to speaker host, Mark McPartland, please go ahead. 00:00:33.182 -- 00:00:37.686 Thank you, operator. Good afternoon, everyone, and welcome to Vistagen's fiscal year 00:00:37.686 -- 00:00:43.211 2025 third quarter corporate update conference call and webcast. 00:00:43.211 -- 00:00:46.995 Earlier this afternoon, we issued a press release for the third quarter of our fiscal 00:00:46.995 -- 00:00:48.717 year 2025 00:00:48.717 -- 00:00:51.179 into December 31st, 2024, 00:00:51.179 -- 00:00:57.237 providing an overview of our progress across our lead clinical neuroscience programs. 00:00:57.237 -- 00:01:01.523 We encourage you to review the release, which can be found in the investor section of 00:01:01.523 -- 00:01:03.663 our website. 00:01:03.887 -- 00:01:08.373 Based on the current expectations information, we will make forelooking statements regarding 00:01:08.373 -- 00:01:13.360 our business during today's call. These forelooking statements speak only as of today, 00:01:13.360 -- 00:01:18.948 except as required by ...